Core Insights - Silexion Therapeutics Corp has selected AMS Advanced Medical Services GmbH as its contract research organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, a next-generation siRNA candidate targeting KRAS-driven solid tumor cancers [1][2][3] - The partnership is expected to enhance Silexion's regulatory submissions to the Israel Ministry of Health in Q4 2025 and to the European Union in Q1 2026, with trials commencing in the first half of 2026 [2][3] - SIL204 has demonstrated up to 97% inhibition rates in preclinical studies across various cancer models, including pancreatic, colorectal, and lung cancers [3][5] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference therapies for cancers driven by the mutated KRAS oncogene, which is prevalent in human cancers [6] - The company aims to advance its lead product candidate for locally advanced pancreatic cancer, building on positive trends observed in previous clinical trials [7] Clinical Development Strategy - The upcoming Phase 2/3 trial will evaluate SIL204's dual-route administration strategy, which combines intratumoral delivery to target primary tumors and systemic administration for metastatic disease [5] - Preclinical data supports the efficacy of SIL204 in significantly reducing both primary tumor growth and metastatic spread in relevant pancreatic cancer models [5] CRO Partnership - AMS brings over 28 years of experience in oncology clinical development and regulatory affairs, which is crucial for executing Silexion's clinical program effectively [2][4] - The collaboration will cover regulatory strategy, clinical trial design, site selection and management, and data analysis for the planned Phase 2/3 study [4]

HOT SPRINGS, Ark., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genesis Cancer and Blood Institute, a partner practice of American Oncology Network (AON), is pleased to welcome medical oncologist Beau Hilton, MD, to its physician care team. He joins an experienced group of physicians including Drs. Timothy Webb, Robert Muldoon, Stephen “Fred” Divers, Lynn Cleveland, Lingyi Chen, Sunil Kakadia, Kristen Sager, Brad Baltz, Jim Chen and Tyler Fugere. Dr. Hilton earned his Doctor of Medicine from the Cleveland Clinic Ler ...

The Oncology Institute (NASDAQ: TOI ) is a company bringing together cancer care practices around the United States. Their main focus is to reduce costs related to oncological treatments and cancer patient management. Their services encompass patient services toAt ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strategy, we help our ...

Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New ChairmanCERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Richard Barasch will retire from his role as Chairman of the Board, effective August 12, 2025. Anne McGeorge, who currently serves as a Board Member and Chair of the Audit Committee, will succeed Barasch in the role. ...

Group 1 - Aptose Biosciences Inc. will hold a reconvened shareholder meeting on August 22, 2025, to vote on the appointment of Ernst & Young LLP as the new independent auditor [1][2] - The selection of Ernst & Young was based on their expertise, capabilities, and understanding of the company's industry [2] - The original meeting held on May 27, 2025, was adjourned to complete the search for a successor independent auditor [1] Group 2 - Only registered shareholders and duly appointed proxyholders as of April 22, 2025, will be entitled to vote and ask questions at the reconvened meeting [3] - Proxies from the original meeting will remain effective unless properly revoked, and new forms of proxies are not being distributed [4] - Registered shareholders who have not previously deposited a form of proxy may do so no later than 48 hours before the reconvened meeting [4] Group 3 - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5] - The company's lead product, tuspetinib (TUS), is being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [5]

VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), has been selected by OneMedNet Corporation (Nasdaq: ONMD) to lead a high-impact data analytics initiative focused on improving how cancer therapies are brought to market. The project focuses on leveraging OneMedNet's regulatory-grade patient dat ...

Core Points - American Oncology Network (AON) has received reaccreditation from the College of American Pathologists (CAP) for its Central Laboratory in Fort Myers, Florida, following a recent on-site inspection [1][3] - CAP accreditation ensures laboratories operate at high levels of accuracy and reliability, contributing to improved patient outcomes and reduced clinical risk [2] - The reaccreditation reflects AON's commitment to quality standards in laboratory medicine, which plays a critical role in modern cancer care [3][4] Company Overview - AON is an alliance of physicians and healthcare leaders focused on the long-term success of community oncology, founded in 2018, representing over 290 providers across 21 states [7] - The organization promotes innovative healthcare solutions through a physician-led model, emphasizing value-based care to improve patient outcomes while reducing costs [7] - AON is dedicated to health equity, addressing disparities in cancer care, and ensuring all patients have access to necessary care for optimal health outcomes [7]

AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancers AON's implementation of BiTE therapies ensures patients across its national network can benefit from these innovations without the need to travel to academic medical centers or major research institutions. How Bispecific Therapies Work: Dual Targeting: Bispecific antibodies are engineered to recognize two targets—typically a cancer cell marker and a T cell receptor. ...

Core Viewpoint - Auerbach Hematology and Oncology Associates PC has joined the American Oncology Network (AON), rebranding as The Center for Cancer and Blood Disorders (CCBD)—Baltimore, to enhance patient services and expand clinical trial offerings [1][11]. Company Overview - Auerbach Hematology and Oncology Associates PC has been providing cancer care in Baltimore for 24 years and is now part of AON, which represents over 290 providers across 21 states [10][11]. - The practice specializes in the diagnosis and treatment of blood disorders and cancer, offering services such as chemotherapy, targeted therapy, immunotherapy, and clinical trials [12]. Leadership and Expertise - Dr. Michael Auerbach, Dr. Huzefa Bahrain, and Stephanie Horrocks are key figures in the practice, with extensive backgrounds in hematology and oncology [3][4][5]. - Dr. Auerbach is recognized for his expertise in iron deficiency anemia and serves as a Clinical Professor at Georgetown University [3]. - Dr. Bahrain is a key opinion leader in intravenous iron treatment and has multiple publications in the field [4]. Partnership Benefits - The partnership with AON allows CCBD to provide innovative, high-quality, and personalized cancer care while maintaining a patient-centered approach [6][9]. - The collaboration aims to enhance service delivery and improve patient outcomes through expanded offerings and resources [6][9]. Community Impact - CCBD serves patients in Baltimore, Bethesda, and Germantown, Maryland, focusing on reducing travel burdens for patients and their families [8]. - The practice features private exam rooms and on-site infusion suites to ensure patient comfort and privacy during treatment [8].

Cancer Research & Treatment Landscape - The field of oncology is moving away from the idea of a universal cure for cancer, recognizing it as a collection of hundreds of different conditions [8][9] - Cancer cells exhibit hallmarks, traits that distinguish them from normal cells, including ignoring signals to stop growing and altering their metabolism [16][17] - Targeted therapies are being developed to address specific genetic mutations in cancer cells, with some achieving cure status for certain cancers like chronic myelogenous leukemia using drugs like Gleevec since 2001 [20][21][22] - Angiogenesis inhibitors, drugs that block the formation of blood vessels towards tumors, are showing promise as a cure for some cancers [22][23] - Immunotherapies, including checkpoint inhibitors and CAR T-cell therapy, are being developed to activate the immune system against cancer [23][24] Importance of Understanding Cancer - Understanding the nuances of cancer is crucial for promoting early detection through screenings for breast, cervical, and colon cancer [29] - Public understanding is essential to support funding for innovative research and policies that advance cancer treatment [30] Clinical & Personal Perspective - Cancer treatment outcomes vary significantly, highlighting the need for personalized approaches [27][28] - The speaker reflects on the challenges of communicating a cancer diagnosis and the desire for better treatments and outcomes [1][31][32] - A patient, Bonnie, lost 40 lbs and underwent multiple surgeries, ultimately passing away due to an aggressive form of cancer [5][31]